The market for biotech IPOs has largely cooled since a first-quarter explosion brought in more than $2 billion, but drug developers Zafgen and Ardelyx managed to turn back the clock in their debuts, cashing out for a combined $156 million.

…read more

Source: Zafgen, Ardelyx bank $156M in IPOs, recalling biotech’s winter boom


0 No comments